Scleroderma Research Foundation
- Assets
- $18.7m
- Revenue
- $8.4m
- Investments
- $0.0
- Employees
- 9
- Location
- San Francisco, CA
- Founding
- 03/1987
- Data as of
- 12/2023
- EIN
- 68-0087234
Organization Overview
Scleroderma Research Foundation is located in San Francisco, CA. The organization was established in 1987. As of 12/2023, Scleroderma Research Foundation employed 9 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Scleroderma Research Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Scleroderma Research Foundation generated $8.4m in total revenue. This organization has experienced exceptional growth, as over the past 9 years, it has increased revenue by an average of 14.4% each year . All expenses for the organization totaled $6.5m during the year ending 12/2023. While expenses have increased by 11.1% per year over the past 9 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2016, Scleroderma Research Foundation has awarded 123 individual grants totaling $15,651,791. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
THE SRF IS LASER-FOCUSED ON FINDING A CURE FOR SCLERODERMA BY RAISING CRITICAL FUNDS FOR RESEARCH INVESTMENTS, FOSTERING COLLABORATION AMONG THE WORLDS TOP SCIENTISTS AND INSTITUTIONS TO DRIVE INNOVATION, AND RAISING AWARENESS ABOUT THIS RARE DISEASE.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE SRF RESEARCH PROGRAM: LED BY A SCIENTIFIC ADVISORY BOARD COMPRISED OF SOME OF THE MOST HIGHLY REGARDED SCIENTISTS IN THE NATION, THE SRFS RESEARCH PROGRAM ACTIVELY SEEKS OUT AND RECRUITS EXPERTS FROM THE FIELDS OF RHEUMATOLOGY, IMMUNOLOGY, GENETICS, AND FIBROSIS, AS WELL AS, EXPERTS IN CUTTING-EDGE TECHNOLOGIES TO JOIN THE SCLERODERMA RESEARCH COMMUNITY. WITH AN INTENSE FOCUS ON IDENTIFYING PROJECTS AND INVESTIGATORS LIKELY TO MOVE SCLERODERMA RESEARCH FORWARD, THE SRF FUNDS A DIVERSE PORTFOLIO OF PROJECTS LED BY TOP-TIER INVESTIGATORS.
CONQUEST IS A GLOBAL, PERPETUAL, CLINICAL TRIAL PLATFORM DEVELOPED BY THE SRF IN COORDINATION WITH PARTNER BIOPHARMACEUTICAL COMPANIES TO ACCELERATE THE CLINICAL DEVELOPMENT OF AGENTS FOR SCLERODERMA. CONQUEST IS DESIGNED TO RAPIDLY ADVANCE PROMISING TREATMENTS FOR SCLERODERMA AND TO IDENTIFY THOSE AGENTS THAT SHOULD PROGRESS FROM PHASE 2B TO PHASE 3 CLINICAL TRIALS. CONQUEST WILL MAKE AN ENDURING CONTRIBUTION TO THE SCLERODERMA COMMUNITY BY CREATING AN ECOSYSTEM DESIGNED TO ENABLE RAPID AND EFFICIENT DEVELOPMENT OF NOVEL DRUGS FOR SCLERODERMA PATIENTS.
SRF EDUCATION & AWARENESS PROGRAM: MANY PATIENTS HEAR THE WORD SCLERODERMA FOR THE FIRST TIME WHEN THEY ARE DIAGNOSED. WE STRIVE TO RAISE AWARENESS AND PROVIDE EDUCATIONAL RESOURCES BECAUSE LACK OF AWARENESS ABOUT SCLERODERMA OFTEN CAUSES DELAYS IN TREATMENT OR MISDIAGNOSIS. AS AN INNOVATOR IN SCLERODERMA RESEARCH, THE SRF IS UNIQUELY QUALIFIED TO PROVIDE THOSE LIVING WITH THIS DISEASE, THE MEDICAL COMMUNITY, AND THE GENERAL PUBLIC WITH THE MOST UP-TO-DATE, TRUSTED AND RELEVANT NEWS AND INFORMATION ABOUT COMPLICATIONS, TREATMENTS, AND RELATED RESEARCH THROUGH OUR WEBSITE, WEBINARS, ANNUAL PATIENT FORUM, AND MONTHLY ENEWSLETTER. AND WE DELIVER STORIES OF IMPACT THAT CONNECT AND INSPIRE PATIENTS, AS WELL AS ADDRESS ISSUES RELATED TO DIVERSITY, EQUITY, AND INCLUSION THAT PATIENTS MAY ENCOUNTER AS THEY NAVIGATE DIAGNOSIS, TREATMENT, AND LIVING WITH THE DISEASE.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Joanne Gold Executive Dir. | OfficerTrustee | 40 | $203,286 |
Kate Ceredona Dir Philanthropy | 40 | $152,315 | |
Gloria Blecha Sr Dir Comm O & Ed | 40 | $129,705 | |
Hannah Young Dir Communications | 40 | $110,376 | |
Luke Evnin PHD Chairman | OfficerTrustee | 30 | $0 |
Deann Wright Secretary | OfficerTrustee | 10 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Kelly Oliver Conquest Consultant | 12/30/23 | $359,375 |
Wade Benton Conquest Consultant | 12/30/23 | $310,000 |
Dahlia Garza Conquest Consultant | 12/30/23 | $230,517 |
Brownemusser Mktg, Adv, Outreach | 12/30/23 | $121,376 |
Ravix Financial Inc Finance & Human Resources | 12/30/23 | $200,121 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $26,279 |
| Membership dues | $0 |
| Fundraising events | $1,141,288 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $2,765,385 |
| Noncash contributions included in lines 1a–1f | $423,912 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $3,932,952 |
| Total Program Service Revenue | $3,832,233 |
| Investment income | $904,546 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | -$258,948 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $8,418,038 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $2,482,921 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $204,561 |
| Compensation of current officers, directors, key employees. | $61,368 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $592,227 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $37,801 |
| Payroll taxes | $56,839 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $298,892 |
| Fees for services: Accounting | $236,971 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $40,277 |
| Fees for services: Other | $1,831,562 |
| Advertising and promotion | $182,044 |
| Office expenses | $93,632 |
| Information technology | $98,241 |
| Royalties | $0 |
| Occupancy | $84,773 |
| Travel | $17,412 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $207,214 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $13,978 |
| Insurance | $8,254 |
| All other expenses | $0 |
| Total functional expenses | $6,487,599 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $3,921,428 |
| Savings and temporary cash investments | $12,296 |
| Pledges and grants receivable | $1,071,849 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $56,574 |
| Net Land, buildings, and equipment | $31,629 |
| Investments—publicly traded securities | $13,488,695 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $72,277 |
| Total assets | $18,654,748 |
| Accounts payable and accrued expenses | $2,842,768 |
| Grants payable | $0 |
| Deferred revenue | $300,849 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $3,978,774 |
| Total liabilities | $7,122,391 |
| Net assets without donor restrictions | $11,531,310 |
| Net assets with donor restrictions | $1,047 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $18,654,748 |
Grants Awarded
Over the last fiscal year, Scleroderma Research Foundation has awarded $2,482,921 in support to 22 organizations.
| Grant Recipient | Amount |
|---|---|
COLUMBIA UNIVERSITY PURPOSE: Research | $23,936 |
BOSTON CHILDRENS HOSPITAL CO PURPOSE: Research | $15,000 |
DUKE UNIVERSITY PURPOSE: Research | $23,794 |
GEORGETOWN UNIV MEDICAL CTR PURPOSE: Research | $35,194 |
HOSPITAL FOR SPECIAL SURGERY PURPOSE: Research | $168,444 |
JOHN HOPKINS UNIVERSITY PURPOSE: Research | $135,090 |